May 2025

Treating Glaucoma Has Evolved in Patients, Physicians Alike: Christine Funke, MD

# Evolution of Glaucoma Treatment: Advancements for Patients and Physicians Glaucoma, often referred to as the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Over the years, the treatment of glaucoma has evolved significantly, offering patients and physicians more effective and less invasive options. From ancient remedies to cutting-edge surgical techniques, […]

Treating Glaucoma Has Evolved in Patients, Physicians Alike: Christine Funke, MD Read More »

Glaucoma, retina, and ophthalmic industry topics kickstart the ASCRS and ASOA Annual Meetings

# Top Glaucoma and Retina Trends at ASCRS & ASOA Annual Meetings The ASCRS & ASOA Annual Meetings are among the most anticipated events in ophthalmology, bringing together leading experts to discuss groundbreaking advancements in eye care. This year, the spotlight was on glaucoma and retina treatments, with innovative technologies, surgical techniques, and pharmaceutical developments

Glaucoma, retina, and ophthalmic industry topics kickstart the ASCRS and ASOA Annual Meetings Read More »

Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma

Rare PTPRB Gene Linked to Eye and Vein Disorders Recent scientific discoveries have shed light on the role of the PTPRB gene in the development of rare eye and vein disorders. This gene, which encodes a protein tyrosine phosphatase, plays a crucial role in vascular development and maintenance. Mutations in PTPRB have now been linked

Rare genetic variation in PTPRB is associated with central serous chorioretinopathy, varicose veins and glaucoma Read More »

Army Hospital introduces 3D microscope for minimally invasive glaucoma surgery –

Army Hospital Pioneers 3D Microscope for Glaucoma Surgery Breakthroughs In a groundbreaking development, an Army hospital has introduced a cutting-edge 3D microscope to revolutionize glaucoma surgery. This innovative technology promises to enhance precision, improve surgical outcomes, and reduce recovery times for patients suffering from this sight-threatening condition. With glaucoma affecting millions worldwide, this advancement could

Army Hospital introduces 3D microscope for minimally invasive glaucoma surgery – Read More »

iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial

# MINIject® Shows 5-Year Efficacy in Glaucoma Treatment in STAR-GLOBAL Trial ## Introduction Glaucoma, a leading cause of irreversible blindness worldwide, has long posed challenges for both patients and ophthalmologists. Traditional treatments, including eye drops and surgical interventions, often come with limitations such as poor patient compliance or invasive procedures. However, a breakthrough in glaucoma

iSTAR Medical’s MINIject® demonstrates significant sustained 5-year efficacy in treating glaucoma in STAR-GLOBAL trial Read More »

Researchers developing ‘minimally invasive’ glaucoma treatments

# Innovative Minimally Invasive Glaucoma Treatments in Development Glaucoma, often called the “silent thief of sight,” is a leading cause of irreversible blindness worldwide. Traditional treatments like eye drops, laser therapy, and invasive surgeries have been the mainstay for decades. However, recent advancements in medical technology are paving the way for minimally invasive glaucoma treatments

Researchers developing ‘minimally invasive’ glaucoma treatments Read More »

Open Angle Glaucoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight

Open Angle Glaucoma Clinical Trials and FDA Approvals 2025 Analysis Open-angle glaucoma (OAG) remains one of the leading causes of irreversible blindness worldwide. As research advances, 2025 is poised to be a pivotal year for clinical trials and FDA approvals in this space. This article delves into the latest developments, emerging therapies, and regulatory milestones

Open Angle Glaucoma Clinical Trials Analysis 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, NICE Approvals, Mechanism of Action, ROA, IND, NDA Approval and Companies by DelveInsight Read More »

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025

Sight Sciences Announces Q1 2025 Financial Results on May 8 Sight Sciences, Inc., a leading innovator in ophthalmology and optometry, has announced that it will release its Q1 2025 financial results on May 8, 2025. This eagerly anticipated update will provide insights into the company’s performance, growth trajectory, and strategic initiatives in the first quarter

Sight Sciences to Report First Quarter 2025 Financial Results on May 8, 2025 Read More »

OcuSciences gains FDA clearance on retinal health scanner

OcuSciences Receives FDA Clearance for Retinal Health Scanner Innovation In a groundbreaking advancement for eye care technology, OcuSciences has received FDA clearance for its revolutionary retinal health scanner. This milestone marks a significant leap forward in early detection and monitoring of retinal diseases, offering hope for millions of patients at risk of vision loss. The

OcuSciences gains FDA clearance on retinal health scanner Read More »

NESC Begins New Software in Eye Healthcare Service in Liberia

NESC Launches Innovative Eye Healthcare Software in Liberia In a groundbreaking move to revolutionize eye healthcare in Liberia, the National Eye Care Services (NESC) has introduced an innovative software solution designed to enhance diagnosis, treatment, and patient management. This cutting-edge technology aims to address the growing need for accessible and efficient eye care services across

NESC Begins New Software in Eye Healthcare Service in Liberia Read More »

Scroll to Top